Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus paclitaxel and nedaplatin for first-line advanced esophageal squamous cell carcinoma
ChiCTR2100046355Phase 2Recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- May 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab, paclitaxel and nedaplatin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: 12-month overall survival rate. Started May 2021; status: recruiting.
02
Drugs
camrelizumabpaclitaxelnedaplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2100046355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046355.